ReviewDiscover nano2026
Integration of nanotechnology in triple negative breast cancer research: a bibliometric and emerging trends analysis.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- African Trypanosomiasis Research at a Crossroads: Bibliometric and Systematic Insights for the Future.Journal of parasitology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a receptor-negative profile and poor prognosis. It mostly affects young African-American, Hispanic women, and BRCA 1 mutation carriers. Nanotechnology, with its capacity to manipulate materials at the nanoscale, offers promising avenues for enhancing therapeutic delivery, imaging, and biomarker detection for better treatment outcomes in TNBC. The purpose of this study was to explore the intellectual landscape, identify key contributors and emerging trends, and predict future research directions in the application of nanotechnology for triple-negative breast cancer (TNBC) research.
methodThe Bibliometrix R package and VOSviewer were used to analyze 405 documents indexed in the Scopus database from 2013 to 2025.
resultsAn annual growth rate of 22.79% was observed, indicating increasing interest in this field. China was the leading country in this field, with Huazhong University of Science and Technology and Zhang Y as the most relevant institution and the most prolific author. Notably, the top 10 most relevant institutions were based in China. The International Journal of Nanomedicine and the Journal of Controlled Release had the highest number of publications, but the latter was the most impactful journal. Emerging trends identified included ferroptosis, immunotherapy, immunogenic cell death, tumor microenvironment, and RNA nanotechnology.
conclusionFurther research into ferroptosis-based therapy for TNBC, immunogenic cell death (ICD) with nano-enabled immunotherapy, multimodal nanotheranostics for TNBC, and clinical translation of NT in TNBC studies is recommended to advance nanotechnology research in TNBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.